Paul Choi
Stock Analyst at Goldman Sachs
(3.16)
# 1,118
Out of 5,147 analysts
106
Total ratings
52.24%
Success rate
0.58%
Average return
Main Sectors:
Stocks Rated by Paul Choi
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RGNX REGENXBIO | Maintains: Neutral | $14 → $12 | $9.04 | +32.74% | 4 | Feb 10, 2026 | |
| VERA Vera Therapeutics | Maintains: Buy | $55 → $95 | $40.79 | +132.90% | 1 | Dec 19, 2025 | |
| CYTK Cytokinetics | Upgrades: Buy | $55 → $95 | $62.22 | +52.68% | 3 | Dec 19, 2025 | |
| PTCT PTC Therapeutics | Maintains: Sell | $44 → $50 | $68.19 | -26.68% | 8 | Nov 5, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Buy | $55 → $100 | $66.48 | +50.42% | 7 | Oct 31, 2025 | |
| KNSA Kiniksa Pharmaceuticals International, | Maintains: Buy | $45 → $55 | $44.49 | +23.62% | 2 | Oct 29, 2025 | |
| ARVN Arvinas | Downgrades: Sell | $8 → $6 | $13.27 | -54.79% | 4 | Oct 15, 2025 | |
| LNTH Lantheus Holdings | Downgrades: Neutral | $110 → $77 | $74.91 | +2.79% | 2 | Oct 8, 2025 | |
| EWTX Edgewise Therapeutics | Initiates: Neutral | $20 | $30.44 | -34.30% | 1 | Sep 25, 2025 | |
| EXEL Exelixis | Initiates: Buy | $47 | $44.06 | +6.67% | 1 | Sep 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $7 → $12 | $13.80 | -13.04% | 9 | Jun 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $16 → $3 | $21.70 | -86.18% | 4 | May 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $7 → $8 | $0.42 | +1,782.80% | 6 | May 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $10 → $5 | $12.56 | -60.19% | 10 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $60 → $52 | $43.23 | +20.29% | 2 | Apr 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $28 → $21 | $9.09 | +131.02% | 8 | Apr 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $4 → $3 | $3.35 | -10.45% | 9 | Apr 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $200 → $225 | $233.50 | -3.64% | 4 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $17 → $19 | $14.33 | +32.59% | 6 | Aug 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $21 → $19 | $5.68 | +234.51% | 3 | Jun 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $43 → $25 | $1.70 | +1,370.59% | 3 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $151 → $170 | $11.52 | +1,375.69% | 2 | Oct 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $9 → $8 | $5.70 | +40.35% | 4 | Aug 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $135 | $132.25 | +2.08% | 1 | Jun 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $270 → $300 | $68.98 | +334.91% | 2 | Mar 30, 2020 |
REGENXBIO
Feb 10, 2026
Maintains: Neutral
Price Target: $14 → $12
Current: $9.04
Upside: +32.74%
Vera Therapeutics
Dec 19, 2025
Maintains: Buy
Price Target: $55 → $95
Current: $40.79
Upside: +132.90%
Cytokinetics
Dec 19, 2025
Upgrades: Buy
Price Target: $55 → $95
Current: $62.22
Upside: +52.68%
PTC Therapeutics
Nov 5, 2025
Maintains: Sell
Price Target: $44 → $50
Current: $68.19
Upside: -26.68%
BridgeBio Pharma
Oct 31, 2025
Maintains: Buy
Price Target: $55 → $100
Current: $66.48
Upside: +50.42%
Kiniksa Pharmaceuticals International,
Oct 29, 2025
Maintains: Buy
Price Target: $45 → $55
Current: $44.49
Upside: +23.62%
Arvinas
Oct 15, 2025
Downgrades: Sell
Price Target: $8 → $6
Current: $13.27
Upside: -54.79%
Lantheus Holdings
Oct 8, 2025
Downgrades: Neutral
Price Target: $110 → $77
Current: $74.91
Upside: +2.79%
Edgewise Therapeutics
Sep 25, 2025
Initiates: Neutral
Price Target: $20
Current: $30.44
Upside: -34.30%
Exelixis
Sep 17, 2025
Initiates: Buy
Price Target: $47
Current: $44.06
Upside: +6.67%
Jun 25, 2025
Maintains: Sell
Price Target: $7 → $12
Current: $13.80
Upside: -13.04%
May 22, 2025
Maintains: Neutral
Price Target: $16 → $3
Current: $21.70
Upside: -86.18%
May 16, 2025
Maintains: Buy
Price Target: $7 → $8
Current: $0.42
Upside: +1,782.80%
May 2, 2025
Maintains: Neutral
Price Target: $10 → $5
Current: $12.56
Upside: -60.19%
Apr 17, 2025
Maintains: Buy
Price Target: $60 → $52
Current: $43.23
Upside: +20.29%
Apr 17, 2025
Maintains: Buy
Price Target: $28 → $21
Current: $9.09
Upside: +131.02%
Apr 17, 2025
Maintains: Neutral
Price Target: $4 → $3
Current: $3.35
Upside: -10.45%
Feb 13, 2025
Maintains: Buy
Price Target: $200 → $225
Current: $233.50
Upside: -3.64%
Aug 1, 2024
Maintains: Neutral
Price Target: $17 → $19
Current: $14.33
Upside: +32.59%
Jun 29, 2023
Maintains: Buy
Price Target: $21 → $19
Current: $5.68
Upside: +234.51%
May 24, 2022
Maintains: Buy
Price Target: $43 → $25
Current: $1.70
Upside: +1,370.59%
Oct 6, 2021
Maintains: Buy
Price Target: $151 → $170
Current: $11.52
Upside: +1,375.69%
Aug 6, 2021
Maintains: Sell
Price Target: $9 → $8
Current: $5.70
Upside: +40.35%
Jun 29, 2020
Downgrades: Neutral
Price Target: $135
Current: $132.25
Upside: +2.08%
Mar 30, 2020
Upgrades: Neutral
Price Target: $270 → $300
Current: $68.98
Upside: +334.91%